ABEO
Price
$5.39
Change
+$0.17 (+3.26%)
Updated
Apr 24 closing price
Capitalization
263.03M
13 days until earnings call
XNCR
Price
$10.84
Change
-$0.03 (-0.28%)
Updated
Apr 24 closing price
Capitalization
771.28M
13 days until earnings call
Ad is loading...

ABEO vs XNCR

Header iconABEO vs XNCR Comparison
Open Charts ABEO vs XNCRBanner chart's image
Abeona Therapeutics
Price$5.39
Change+$0.17 (+3.26%)
Volume$1.35M
Capitalization263.03M
Xencor
Price$10.84
Change-$0.03 (-0.28%)
Volume$618.49K
Capitalization771.28M
ABEO vs XNCR Comparison Chart
Loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABEO vs. XNCR commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABEO is a Buy and XNCR is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (ABEO: $5.39 vs. XNCR: $10.84)
Brand notoriety: ABEO and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABEO: 210% vs. XNCR: 74%
Market capitalization -- ABEO: $263.03M vs. XNCR: $771.28M
ABEO [@Biotechnology] is valued at $263.03M. XNCR’s [@Biotechnology] market capitalization is $771.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABEO’s FA Score shows that 0 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • ABEO’s FA Score: 0 green, 5 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, ABEO is a better buy in the long-term than XNCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABEO’s TA Score shows that 6 TA indicator(s) are bullish while XNCR’s TA Score has 5 bullish TA indicator(s).

  • ABEO’s TA Score: 6 bullish, 3 bearish.
  • XNCR’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ABEO is a better buy in the short-term than XNCR.

Price Growth

ABEO (@Biotechnology) experienced а +11.36% price change this week, while XNCR (@Biotechnology) price change was +11.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

ABEO is expected to report earnings on Aug 18, 2025.

XNCR is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XNCR($771M) has a higher market cap than ABEO($263M). ABEO YTD gains are higher at: -3.232 vs. XNCR (-52.829). ABEO has higher annual earnings (EBITDA): -64.95M vs. XNCR (-186.17M). XNCR has more cash in the bank: 498M vs. ABEO (110M). ABEO has less debt than XNCR: ABEO (23.1M) vs XNCR (232M). XNCR has higher revenues than ABEO: XNCR (110M) vs ABEO (0).
ABEOXNCRABEO / XNCR
Capitalization263M771M34%
EBITDA-64.95M-186.17M35%
Gain YTD-3.232-52.8296%
P/E RatioN/AN/A-
Revenue0110M-
Total Cash110M498M22%
Total Debt23.1M232M10%
FUNDAMENTALS RATINGS
ABEO vs XNCR: Fundamental Ratings
ABEO
XNCR
OUTLOOK RATING
1..100
188
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
4791
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABEO's Valuation (60) in the Pharmaceuticals Generic industry is in the same range as XNCR (79) in the Biotechnology industry. This means that ABEO’s stock grew similarly to XNCR’s over the last 12 months.

ABEO's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as XNCR (100) in the Biotechnology industry. This means that ABEO’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's SMR Rating (94) in the Biotechnology industry is in the same range as ABEO (98) in the Pharmaceuticals Generic industry. This means that XNCR’s stock grew similarly to ABEO’s over the last 12 months.

ABEO's Price Growth Rating (47) in the Pharmaceuticals Generic industry is somewhat better than the same rating for XNCR (91) in the Biotechnology industry. This means that ABEO’s stock grew somewhat faster than XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for ABEO (100) in the Pharmaceuticals Generic industry. This means that XNCR’s stock grew significantly faster than ABEO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABEOXNCR
RSI
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
71%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
66%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
70%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 3 days ago
71%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 18 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
68%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
81%
View a ticker or compare two or three
Ad is loading...
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ITHSX47.57N/A
N/A
Hartford Capital Appreciation R4
MUESX29.94N/A
N/A
MFS Blended Research Core Equity R2
LMGAX22.04N/A
N/A
Lord Abbett Growth Opportunities A
NCBVX18.24N/A
N/A
PGIM Quant Solutions Mid-Cap Val C
PQJCX12.28N/A
N/A
PGIM Jennison Small-Cap Core Equity R6

ABEO and

Correlation & Price change

A.I.dvisor tells us that ABEO and RZLT have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ABEO and RZLT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
+3.26%
RZLT - ABEO
31%
Poorly correlated
-0.25%
AXON - ABEO
31%
Poorly correlated
+2.39%
MLEC - ABEO
29%
Poorly correlated
-5.13%
SCPH - ABEO
29%
Poorly correlated
-3.85%
XNCR - ABEO
29%
Poorly correlated
-0.28%
More